Treatment of Suprapubic Tube Infection with Pseudomonas and Providencia
For a patient with a suprapubic tube infected with both Pseudomonas aeruginosa and Providencia species, treat with an antipseudomonal beta-lactam (ceftazidime, cefepime, or piperacillin-tazobactam) combined with an aminoglycoside (amikacin or tobramycin), adjusting based on susceptibility results once available 1.
Rationale and Treatment Approach
This is a complicated urinary tract infection (cUTI) by definition due to the presence of an indwelling suprapubic catheter, which creates a challenging environment for bacterial eradication 1. Both organisms are notorious for causing catheter-associated infections and developing multidrug resistance 2.
Initial Empiric Therapy
Start with parenteral combination therapy using:
- Primary option: Ceftazidime 2 g IV every 8 hours OR Cefepime 2 g IV every 8-12 hours OR Piperacillin-tazobactam 4.5 g IV every 6-8 hours
- PLUS: Amikacin 15 mg/kg IV once daily OR Tobramycin 5 mg/kg IV once daily
The combination approach is critical here because 3, 4:
- Pseudomonas aeruginosa infections, particularly in complicated UTIs, benefit from combination therapy with aminoglycosides plus beta-lactams to achieve synergy
- This reduces the risk of treatment failure and emergence of resistance during therapy
- Providencia species (particularly P. stuartii and P. rettgeri) are commonly found in long-term catheterized patients and often exhibit multidrug resistance 2
Key Clinical Considerations
Obtain susceptibility testing immediately - both organisms can exhibit unpredictable resistance patterns. Providencia species show variable susceptibility to fluoroquinolones 5, and Pseudomonas resistance patterns vary significantly by institution 6.
If the patient is clinically stable and susceptibilities return showing sensitivity, you may consider:
- Transitioning to fluoroquinolone monotherapy (ciprofloxacin 400 mg IV every 12 hours or levofloxacin 750 mg IV daily) if both organisms are susceptible 1
- However, maintain combination therapy if there is any concern about resistance or if the patient has severe sepsis
For multidrug-resistant isolates revealed on culture:
- Consider ceftolozane-tazobactam 1.5 g IV every 8 hours, ceftazidime-avibactam 2.5 g IV every 8 hours, or cefiderocol 2 g IV every 8 hours 1, 7, 8
- These newer agents have enhanced activity against difficult-to-treat resistant Pseudomonas (DTR-P. aeruginosa)
Duration and Source Control
Treatment duration: 7-14 days depending on clinical response and whether source control is achieved 1.
Critical pitfall: Antibiotics alone will likely fail without addressing the suprapubic tube. Consider:
- Replacing or removing the catheter if feasible, as biofilm formation on the catheter surface makes eradication nearly impossible 2
- If the tube must remain, expect potential recurrence even with appropriate antibiotics
- Providencia stuartii particularly thrives in the long-term catheterized urinary tract and may persist despite treatment 2
Monitoring
- Reassess clinical status at 48-72 hours
- If fever persists beyond 72 hours, obtain imaging (CT with contrast) to evaluate for complications such as abscess or obstruction 1
- Repeat cultures after treatment completion are reasonable given the high-risk setting
Avoid monotherapy with oral agents (nitrofurantoin, fosfomycin) as these have insufficient data for complicated infections and will not achieve adequate tissue penetration for systemic involvement 1.